Halozyme Therapeutics Coverage Initiated at Citigroup Inc. (HALO)
Investment analysts at Citigroup Inc. initiated coverage on shares of Halozyme Therapeutics (NASDAQ:HALO) in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
HALO has been the subject of a number of other recent research reports. Analysts at Citic Securities Co., Ltd reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday. They now have a $12.00 price target on the stock. Separately, analysts at BMO Capital Markets reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, April 4th. Finally, analysts at Jefferies Group raised their price target on shares of Halozyme Therapeutics from $4.00 to $4.50 in a research note on Monday, January 27th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Halozyme Therapeutics currently has an average rating of “Buy” and a consensus price target of $11.25.
Shares of Halozyme Therapeutics (NASDAQ:HALO) opened at 7.19 on Tuesday. Halozyme Therapeutics has a 52 week low of $5.47 and a 52 week high of $18.18. The stock has a 50-day moving average of $12.5 and a 200-day moving average of $13.44. The company’s market cap is $818.9 million.
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02. The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $21.80 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was down 42.7% on a year-over-year basis. On average, analysts predict that Halozyme Therapeutics will post $-0.45 earnings per share for the current fiscal year.
Halozyme Therapeutics, Inc is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.